Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) EBT (2019 - 2025)

Historic EBT for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' EBT fell 3040.62% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 1304.89%. This contributed to the annual value of -$105.2 million for FY2024, which is 1983.64% up from last year.
  • As of Q3 2025, C4 Therapeutics' EBT stood at -$32.2 million, which was down 3040.62% from -$26.0 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' EBT peaked at -$15.7 million during Q4 2021, and registered a low of -$37.2 million during Q4 2022.
  • Over the past 5 years, C4 Therapeutics' median EBT value was -$26.9 million (recorded in 2022), while the average stood at -$28.0 million.
  • In the last 5 years, C4 Therapeutics' EBT tumbled by 13748.24% in 2022 and then soared by 5068.2% in 2024.
  • Quarter analysis of 5 years shows C4 Therapeutics' EBT stood at -$15.7 million in 2021, then crashed by 137.48% to -$37.2 million in 2022, then increased by 7.28% to -$34.5 million in 2023, then rose by 0.1% to -$34.4 million in 2024, then rose by 6.61% to -$32.2 million in 2025.
  • Its EBT was -$32.2 million in Q3 2025, compared to -$26.0 million in Q2 2025 and -$26.3 million in Q1 2025.